NYXH Nyxoah SA IFRS
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1857190 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | 2025Q2*2025-06-30 | 2024Q22024-06-30 | 2023Q22023-06-30 | 2022Q4*2022-12-31 | 2022Q32022-09-30 | 2022Q22022-06-30 | 2021Q4*2021-12-31 | 2021Q32021-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 1.34M | 771,000 | 1.11M | 1.31M | 182,000 | 936,000 | 343,000 | 203,000 |
| Cost of revenue | 490,000 | 281,000 | 419,000 | 465,000 | 63,000 | 334,000 | 105,000 | 82,000 |
| Gross profit | 850,000 | 490,000 | 688,000 | 842,000 | 119,000 | 602,000 | 190,000 | 121,000 |
| R&D expense | 10.06M | 7.47M | 6.61M | 4.58M | 4.22M | 3.47M | 3.33M | 3.52M |
| SG&A expense | 10.67M | 6.38M | 6.18M | 5.36M | 4.76M | 4.54M | 3.94M | 4.50M |
| Operating income | -19.85M | -13.31M | -11.88M | -9.05M | -8.78M | -7.39M | -6.54M | -8.07M |
| Interest expense | 3.34M | 1.45M | 775,000 | -1.15M | 2.52M | 2.16M | 588,000 | 585,000 |
| Pretax income | -20.33M | -12.68M | -11.87M | -12.51M | -6.17M | -4.88M | -3.53M | -8.63M |
| Income tax | 278,000 | 441,000 | 928,000 | 790,000 | 65,000 | 107,000 | 2.72M | 136,000 |
| Net income | -20.61M | -13.12M | -12.80M | -13.30M | -6.24M | -4.99M | -6.25M | -8.76M |
| EPS (basic) | -0.55 | -0.43 | -0.45 | — | -0.24 | -0.19 | — | -0.35 |
| EPS (diluted) | -0.55 | -0.43 | -0.45 | — | -0.24 | -0.19 | — | -0.35 |
| Balance sheet | ||||||||
| Cash & equivalents | 22.73M | 27.72M | 16.60M | 17.89M | 89.88M | 75.60M | 135.51M | 140.91M |
| Receivables | 1.33M | 2.61M | 1.82M | 1.46M | 757,000 | — | 226,000 | — |
| Inventory | 5.33M | 5.10M | 1.15M | 882,000 | 594,000 | — | 346,000 | — |
| Current assets | 55.11M | 89.67M | 91.33M | 100.26M | 119.34M | — | 140.06M | — |
| PP&E, netmay include right-of-use assets (IFRS) | 5.01M | 4.39M | 2.81M | 2.46M | 2.22M | — | 2.02M | — |
| Intangibles | 51.41M | 49.31M | 44.49M | 39.97M | 36.49M | — | 25.32M | — |
| Total assets | 116.47M | 148.23M | 142.41M | 146.07M | 164.07M | — | 170.83M | — |
| Current liabilities | 20.95M | 16.38M | 15.24M | 14.91M | 20.01M | — | 11.57M | — |
| Total liabilities | 43.07M | 28.09M | 26.84M | 25.75M | 31.00M | — | 22.21M | — |
| Shareholders' equity | 73.40M | 120.14M | 115.58M | 120.32M | 133.07M | — | 148.62M | — |
| Shares outstanding | 37.44M | 34.37M | 28.66M | 25.85M | 25.85M | 25.84M | 25.77M | 25.55M |
| Cash flow statement | ||||||||
| Operating cash flow | — | — | — | -10.37M | -8.66M | — | -7.33M | — |
| Capital expenditure | — | — | — | 402,000 | 182,000 | — | 212,000 | — |
| Free cash flow | — | — | — | -10.77M | -8.85M | — | -7.54M | — |
| Investing cash flow | — | — | — | -58.30M | 20.34M | — | -3.34M | — |
| Financing cash flow | — | — | — | -219,000 | -399,000 | — | 1.43M | — |
| Stock-based compensation | 887,000 | 540,000 | — | 562,000 | 845,000 | — | 345.22M | 784,000 |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.